相关临床试验
156
5 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1855
进行中（未招募）
1
0.6%
已完成
127
81.4%
尚未招募
4
2.6%
招募中
10
6.4%
终止
4
2.6%
Unknown
8
5.1%
撤回
2
1.3%
暂无批准数据
- TLC-2716, an oral liver X receptor inverse agonist, demonstrated significant lipid-lowering effects in a 14-day Phase 1 trial involving 100 healthy adults. - The drug reduced triglycerides by up to 38.5% and postprandial remnant cholesterol by up to 61% at the highest doses tested. - TLC-2716 specifically targets liver and gut LXR activity while avoiding systemic effects, addressing a long-standing challenge in lipid metabolism drug development. - All doses were well tolerated with no serious adverse events, supporting progression to Phase 2 trials in patients with hypertriglyceridemia and metabolic dysfunction-associated steatotic liver disease.
- Researchers have developed sand-grain-sized microrobots that can swim through blood vessels using magnetic guidance to deliver drugs with millimeter precision before dissolving safely in the body. - The gelatin-based robots demonstrated over 95% accuracy in drug delivery to correct locations during trials in pigs and sheep, representing a significant advance toward clinical translation. - The technology addresses a critical need in drug development, where approximately one-third of developed drugs fail due to toxicity from systemic exposure rather than targeted delivery. - The modular platform integrates electromagnetic navigation, real-time X-ray tracking, and biodegradable materials, potentially enabling clinical applications within five to ten years.
